BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor
Daniel Meibom(Bayer (Germany)), Dmitry Zubov(Bayer (Germany)), Joachim Mittendorf(Bayer (Germany)), Afra Torge(Bayer (Germany)), Martina Schaefer(Bayer (Germany)), Pierre Wasnaire(Bayer (Germany)), Yolanda Cancho‐Grande(Bayer (Germany)), Natalia A. Jungmann(Bayer (Germany)), Kristin Beyer(Bayer (Germany)), Niels Lindner(Bayer (Germany)), Bryan T. MacDonald(Broad Institute), Eric Stefan(Broad Institute), Tanja Krainz(Broad Institute), Sarah Johannes(Bayer (Germany)), Kerstin Henninger(Bayer (Germany)), Andreas Broehl(Bayer (Germany)), Stefanie Maassen(Bayer (Germany)), Yi Xing(Broad Institute), Denis Menshykau(SIB Swiss Institute of Bioinformatics), Guzmán Sánchez, Nadine H. Elowe(Broad Institute)
Cited by 11
Related Papers
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
|Nature Cancer|2020|880
Frizzled and LRP5/6 Receptors for Wnt/ -Catenin Signaling
|Cold Spring Harbor Perspectives in Biology|2012|610
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
|Nature Medicine|2002|328
Ring-Strain-Enabled Reaction Discovery: New Heterocycles from Bicyclo[1.1.0]butanes
|Accounts of Chemical Research|2015|292
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension
|European Respiratory Journal|2008|234